PATENT CLAIM ANALYSIS

Application Number: 15882455
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "184100"]

Abstract:
The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.

Claim (Index 4):
The method according to  claim 2 , wherein said infectious diseases are selected from rhodoccus pneumonia, strangles, African horse sickness, West Nile Virus infection, dermatophytosis, parasites, cryptosporidiosis, helminths and/or their prepatent stages.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 86.0
- Lexical Diversity: 1.61194
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15520676', '11474180', '11601687', '11886577', '11102883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6616784608683458
- 35 USC 102 Novelty (BERT): 0.5211592599759927
- Combined Prediction Score: 0.6476265407791105
- Mean Citation Score: 226.108516
- Max Citation Score: 243.88051
- Similarity Product: 140.20316238711118

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test